Teva Pharmaceutical Industries (TEVA) Operating Income (2016 - 2026)
Teva Pharmaceutical Industries (TEVA) posted Operating Income of $652.0 million for Q1 2026, up 117.33% on a QoQ basis from $300.0 million in Q4 2025, and up 25.63% year-over-year from $519.0 million in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Operating Income (2016 - 2026) Analysis & Trends
Teva Pharmaceutical Industries' Operating Income history runs 11 years deep, the most recent figure standing at $652.0 million for Q1 2026.
- Quarterly Operating Income rose 25.63% year-over-year to $652.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 427.42% YoY) and the FY2025 annual result came in at $2.2 billion, up 811.88% from the prior year.
- Operating Income was $652.0 million for Q1 2026 at Teva Pharmaceutical Industries, up from $300.0 million in the prior quarter.
- Across five years, Operating Income topped out at $882.0 million in Q3 2025 and bottomed at -$967.0 million in Q2 2022.
- A 5-year average of $43.6 million and a median of -$5.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 1576.92% — and 2025, when it surged 9200.0%.
- Teva Pharmaceutical Industries' Operating Income stood at -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then plunged by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025, then jumped by 117.33% to $652.0 million in 2026.
- Business Quant data shows TEVA's Operating Income at $652.0 million in Q1 2026, $300.0 million in Q4 2025, and $882.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 652.00 Mn |
| Dec 31, 2025 | 300.00 Mn |
| Sep 30, 2025 | 882.00 Mn |
| Jun 30, 2025 | 455.00 Mn |
| Mar 31, 2025 | 519.00 Mn |
| Dec 31, 2024 | -29.00 Mn |
| Sep 30, 2024 | -51.00 Mn |
| Jun 30, 2024 | -5.00 Mn |
| Mar 31, 2024 | -218.00 Mn |
| Dec 31, 2023 | 756.00 Mn |
| Sep 30, 2023 | 344.00 Mn |
| Jun 30, 2023 | -654.00 Mn |
| Mar 31, 2023 | -13.00 Mn |
| Dec 31, 2022 | -940.00 Mn |
| Sep 30, 2022 | 424.00 Mn |
| Jun 30, 2022 | -967.00 Mn |
| Mar 31, 2022 | -713.00 Mn |
| Dec 31, 2021 | 78.00 Mn |
| Sep 30, 2021 | 623.00 Mn |
| Jun 30, 2021 | 582.00 Mn |